Overview

ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Status:
Not yet recruiting

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the time of response, sustained remission rate, and relapse rate of CD38 monoclonal antibody (Daratumumab) combined with SCT800 (rFVIII) in the treatment of hemophilia A adolescents and adults with high titer inhibitors.

Phase:

Phase 4

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital

Collaborator:

Sinocelltech Ltd.

Treatments:

Daratumumab